BF-168

• CAT Number: I019802
• CAS Number: 634911-47-0
• Molecular Formula: C18H17FN2O2
• Molecular Weight: 312.34
• Purity: ≥95%
• Synonyms: 4-[(E)-2-[6-(2-fluoroethoxy)-1,3-benzoxazol-2-yl]ethenyl]-N-methylaniline
• InChI: InChI=1S/C18H17FN2O2/c1-20-14-5-2-13(3-6-14)4-9-18-21-16-8-7-15(22-11-10-19)12-17(16)23-18/h2-9,12,20H,10-11H2,1H3/b9-4+
• InChIKey: FJCPWUDGNYOGQR-RUDMXATFSA-N
• SMILES: CNC1=CC=C(C=C1)C=CC2=NC3=C(O2)C=C(C=C3)OCCF

BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42.
BF-168, a styrylbenzoxazole derivative, is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42[1].
Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice result in specific in vivo labeling to both compact and diffuse amyloid deposits in the brain. In addition, 18F-radiolabeled BF-168 demonstrates abundant initial brain uptake (3.9% injected dose/gm at 2 min after injection) and fast clearance (t1/2=24.7 min) after intravenous administration in normal mice. Furthermore, autoradiograms of brain sections from APP23 transgenic mice at 180 min after intravenous injection of [18F]BF-168 shows selective labeling of brain amyloid deposits with little nonspecific binding[1].

Reference

[1]. Okamura N, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004 Mar 10;24(10):2535-41.
 [Content Brief]